EF Hutton Reiterates Buy on G1 Therapeutics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a price target of $19.
August 04, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on G1 Therapeutics and maintained a price target of $19.
The reiteration of a 'Buy' rating by EF Hutton, a well-known financial analyst, is a positive signal for G1 Therapeutics. The maintained price target of $19 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100